Varicella-Zoster IgG Ab
Test Mnemonic
VZVG2
CPT Codes
- 86787 - QTY (1)
LOINC ®
8047-3
Aliases
- VZV Antibody, IgG
Performing Laboratory
Cleveland Clinic Laboratories
FDA Category
In Vitro Diagnostic
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Gold) | Ambient | Refrigerated |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 3 days |
| Refrigerated | 7 days |
| Frozen | 30 days |
Days Performed
Mon - Fri
Turnaround Time
1 - 4 days
Methodology
| Name | Description |
|---|---|
| Immunochemiluminometric Assay (ICMA) |
Reference Range
| Varicella Zoster Virus Signal-to-cutoff | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | <1.00 |
Special Info
Avoid using hemolyzed, lipemic, icteric or bacterially contaminated sera. Do not use heat inactivated sera.
Clinical Info
A negative result does not rule out acute infection. If exposure to Varicella-Zoster virus is suspected, despite a negative finding, a second sample should be collected and tested no less than one-two weeks later. A positive result generally indicates exposure to the pathogen or administration of specific immunoglobulins, but is no indication of active infection or stage of disease. The results are not by themselves diagnostic and should be considered in association with other clinical data and patient symptoms. Screening of the general population leads to no appreciable diagnostic advantage. The performance characteristics with individuals vaccinated with VZV (ROD strain) have not been established.
Clinical Limitation
Results from immunosuppressed patients should be interpreted with caution.